Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study

BMJ : British Medical Journal
Sophia ZackrissonJens Peter Garne

Abstract

To evaluate the rate of over-diagnosis of breast cancer 15 years after the end of the Malmö mammographic screening trial. Follow-up study. Malmö, Sweden. 42 283 women aged 45-69 years at randomisation. Screening for breast cancer with mammography or not (controls). Screening was offered at the end of the randomisation design to both groups aged 45-54 at randomisation but not to groups aged 55-69 at randomisation. Rate of over-diagnosis of breast cancer (in situ and invasive), calculated as incidence in the invited and control groups, during period of randomised design (period 1), during period after randomised design ended (period 2), and at end of follow-up. In women aged 55-69 years at randomisation the relative rates of over-diagnosis of breast cancer (95% confidence intervals) were 1.32 (1.14 to 1.53) for period 1, 0.92 (0.79 to 1.06) for period 2, and 1.10 (0.99 to 1.22) at the end of follow-up. Conclusions on over-diagnosis of breast cancer in the Malmö mammographic screening trial can be drawn mainly for women aged 55-69 years at randomisation whose control groups were never screened. Fifteen years after the trial ended the rate of over-diagnosis of breast cancer was 10% in this age group.

References

Oct 15, 1988·BMJ : British Medical Journal·I AnderssonB Sigfússon
Feb 6, 2003·British Journal of Cancer·A H OlsenE Lynge
Jul 31, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M-F YenS W Duffy
Dec 30, 2003·International Journal of Cancer. Journal International Du Cancer·Sophia ZackrissonLars Janzon
Feb 24, 2005·The Breast Journal·Cornelia J Baines
Mar 24, 2005·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·B MøllerT Haldorsen
Jun 16, 2005·International Journal of Cancer. Journal International Du Cancer·Håkan JonssonPer Lenner
Sep 15, 2005·Journal of Medical Screening·Stephen W Duffy
Sep 20, 2005·Breast Cancer Research : BCR·Nick E Day
Oct 28, 2005·The New England Journal of Medicine·Donald A BerryUNKNOWN Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators

❮ Previous
Next ❯

Citations

Aug 3, 2010·International Journal of Colorectal Disease·Göran EkelundSophia Zackrisson
Feb 3, 2007·Breast Cancer Research and Treatment·Sylvie BérubéJacques Brisson
Nov 7, 2009·Cancer Causes & Control : CCC·Stephen MorrellBruce Armstrong
Nov 28, 2009·Nature Reviews. Clinical Oncology·Andrea Veronesi, Diego Serraino
Aug 3, 2011·Nature Reviews. Clinical Oncology·Steven A Narod
Sep 24, 2010·The New England Journal of Medicine·H Gilbert Welch
Nov 23, 2012·The New England Journal of Medicine·Archie Bleyer, H Gilbert Welch
Jun 24, 2011·Epidemiologic Reviews·Suzanne W Fletcher
Jun 29, 2011·Epidemiologic Reviews·Rianne de GelderHarry J de Koning
Jul 27, 2007·Journal of the National Cancer Institute·Donald A Berry, Peter M Ravdin
Feb 14, 2008·Journal of the National Cancer Institute·H Gilbert WelchLisa M Schwartz
Jul 31, 2008·Journal of the National Cancer Institute·Solveig HofvindBerta M Geller
Mar 12, 2009·Journal of the National Cancer Institute·Michael J Barry, Albert J Mulley
Aug 13, 2009·Journal of the National Cancer Institute·Steven Woloshin, Lisa M Schwartz
Sep 2, 2009·Journal of the National Cancer Institute·H Gilbert Welch, Peter C Albertsen
Apr 24, 2010·Journal of the National Cancer Institute·H Gilbert Welch, William C Black
Sep 19, 2012·Journal of the National Cancer Institute·Eitan AmirBostjan Seruga
Aug 15, 2009·Journal of Public Health·Victoria H CouplandHenrik Møller
Apr 9, 2008·American Journal of Clinical Oncology·Xianglin L DuDejian Lai
Oct 28, 2010·Current Opinion in Obstetrics & Gynecology·Kimberly D Gregory, George F Sawaya
Mar 28, 2006·BMJ : British Medical Journal·Les IrwigPaul Glasziou
Mar 28, 2006·BMJ : British Medical Journal·H Gilbert WelchSteven Woloshin
Mar 28, 2006·BMJ : British Medical Journal·Michael Baum
Mar 7, 2006·BMJ : British Medical Journal·Henrik Møller, Elizabeth Davies
Oct 13, 2007·BMJ : British Medical Journal·Lisa M Schwartz, Steven Woloshin
Feb 28, 2013·BMJ : British Medical Journal·Sisse Helle NjorElsebeth Lynge
Sep 23, 2008·Annual Review of Medicine·Barnett S Kramer, Jennifer Miller Croswell
Jul 23, 2011·Breast Care·Sylvia H Heywang-KöbrunnerStefan Sedlacek
Jan 30, 2008·BMC Public Health·Ahti AnttilaSirpa Heinävaara
Aug 5, 2010·Breast Cancer Research : BCR·Montserrat Martinez-AlonsoMontserrat Rue
Feb 6, 2014·PloS One·Ester VilaprinyoUNKNOWN Interval Cancer (INCA) Study Group
Nov 19, 2009·Annals of Internal Medicine·Heidi D NelsonUNKNOWN U.S. Preventive Services Task Force

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.